June 10, 2016

‘Tide has turned’ in AML: Better understanding of disease biology may lead to treatment advances
Healio – June 10
“We now understand a lot more about the biology — and, in particular, the molecular genetics — of AML and the uniqueness of each individual patient’s disease,” Jeffrey E. Lancet, MD, section head of leukemia and myelodysplasia at Moffitt Cancer Center, told HemOnc Today.

Moffitt Breast Cancer Risk Management Study
Bay News 9 – June 9
The Moffitt study showed significant differences in how white, Hispanic and Black women acted on their positive mutation results. 

ASCO 2016 Multiple Myeloma Update – Days Four & Five – Potential New Myeloma Therapies
The Myeloma Beacon – June 9
The selinexor study presented in Monday is being conducted by researchers at the Moffitt Cancer Center in Tampa, Florida. 

Black Breast Cancer Survivors Less Likely to Receive Preventive Care
Cancer Network – June 9
“Young black women with breast cancer are much less likely to have BRCA testing and to undergo risk-reducing salpingo-oophorectomy if they carry a BRCA mutation,” said lead author Tuya Pal, MD, a clinical geneticist at the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida, at a press briefing.

ASCO 2016 Multiple Myeloma Update – Days Four & Five – Potential New Myeloma Therapies
The Myeloma Beacon – June 9
The selinexor study presented in Monday is being conducted by researchers at the Moffitt Cancer Center in Tampa, Florida. Thus far, the trial has recruited 13 patients, who have had a median of six prior treatment regimens (which probably is equivalent to a median of 4 or 5 prior lines of therapy).

Lisa A. Carey, MD, and Tuya Pal, MD, on BRCA Carriers: The Disparities in Management

The ASCO Post – June 8
Lisa A. Carey, MD, of the University of North Carolina, and Tuya Pal, MD, of H. Lee Moffitt Cancer Center & Research Institute, discuss the racial disparities in cancer risk management among BRCA carriers across a diverse sample of young black, Hispanic, and non-Hispanic white breast cancer survivors (Abstract LBA1504).

Black women with breast cancer less likely to undergo BRCA testing, risk-reducing surgery
Healio –June 8
“Young black women with breast cancer were much less likely to have BRCAtesting and to undergo risk-reducing salpingo-oophorectomy if they carried aBRCA mutation,” Tuya Pal, MD, clinical geneticist at the H. Lee Moffitt Cancer and Research Institute, said at a press briefing. “Our findings were a snapshot of data between 2009 and 2012, which align with previous research.”

BRCA-Positive Black Women With Breast Cancer Less Likely to Undergo Risk-Reducing Surgery
Cure Magazine – June 8
“We need to understand the reasons for these findings,” said lead study author Tuya Pal, a clinical geneticist at the Moffitt Cancer Center in Tampa, Florida. Ultimately, it’s the patient who must decide whether to have genetic testing and take prophylactic measures for risk management, Pal said.

A limb is saved, a life is changed as Moffitt Cancer Center works to perfect a targeted blast of chemo
Tampa Bay Times – June 8
But four days before the amputation, the doctor in Houston called with a last-ditch proposal: Would Hladky consider an obscure procedure at the Moffitt Cancer Center in Tampa that might shrink his tumor and save his arm? He booked a flight to Florida the next day.

Lower health risks: eat a rainbow of fruits, veggies
Tallahassee Democrat – June 8
According to Moffitt Cancer Center and a recent study published in Nature*, 70-90 percent of gene mutations that cause cancers can be avoided through preventable lifestyle factors, limiting environmental exposures and other controllable factors.

Black Women Less Likely to Pursue BRCA Testing and Cancer Risk Reduction Measures
Targeted Oncology – June 7
“We need to understand the reasons for these findings,” said lead study author Tuya Pal, MD, a clinical geneticist at the Moffitt Cancer Center in Tampa, Florida.

Mediterranean diet may reduce risk of breast cancer returning, study suggests
The Villages Sun Times – June 8
Dr Scott Antonia, from the Moffitt Cancer Center in the United States, is studying small cell lung cancer, which is hard treat if it returns after chemotherapy.

Diabetes drug metformin, a new weapon against cancer
Ambienta Ja – June 8
Dr Scott Antonia, from the Moffitt Cancer Center in the U.S., is studying small cell lung cancer, which is hard treat if it returns after chemotherapy. "The median survival is about 3 years, and more than 40,000 people die annually, accounting for 7% of all USA cancer deaths. But for other blood cancer types, such as CLL, we have made progress, but still have some way to go", he added.

Colon Cancer is second leading cause of death in African-Americans
WSB Radio – June 8
Colon cancer is the second leading cause of death in America at for African Americans. But Doctor David Obama at Moffitt cancer Center in Tampa Florida said it doesn't have to be a death sentence.

U.S. Black Women Get Less Care to Prevent Breast Cancer Return
HealthDay  – June 7
"I hope that our findings will raise awareness of disparities pertaining to inherited cancer predispositions, that exist across the cancer care continuum," said study leader Dr. Tuya Pal. She is a clinical geneticist at the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Fla.

Study: Minorities less likely to get Ca risk management
Medpage Today – June 7
Black women were significantly less likely than whites or Hispanics to get tested for the BRCA mutations that confer a markedly higher lifetime risk of both breast and ovarian cancer, according to Tuya Pal, MD, of the H. Lee Moffitt Cancer and Research Institute in Tampa, Fla.

Study Finds Racial Disparities in Breast and Ovarian Cancer Risk Management
Oncology Nurse Advisor – June 7
The racial disparities in uptake of risk-reducing prophylactic oophorectomy observed among blacks is particularly concerning, given that it “is strongly recommended as the main ovarian cancer prevention option due to the absence of effective early detection methods,” said Tuya Pal, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.

Targeted cancer care to spare patients chemo
Farundu Life – June 7
Dr Scott Antonia, from the Moffitt Cancer Center in the United States, is studying small cell lung cancer, which is hard treat if it returns after chemotherapy

Sense of place, history motivate Tampa native in recreating iconic restaurants
83 Degrees Media – June 7
A devoted father and grandfather, Gonzmart is also known as a generous philanthropist who believes strongly in giving back to his native city, such as supporting his alma mater, Jesuit High School,  and Melanie’s Academy of Holy Names, to fundraisers for Moffitt Cancer Center, where he underwent successful treatment for his prostate cancer in 2013. 

Richard’s Father’s Day Family Walk/Jog 2016: What to know before you go
Tampa Patch – June 7, 2016
Through the Gonzmart Family Foundation, 100 percent of the proceeds from the annual event supports cancer research at Moffitt Cancer Center.

Black Women Who Are BRCA Carriers Less Likely to Pursue Breast and Ovarian Cancer Risk Reduction
OncLive – June 6
“We need to understand the reasons for these findings,” said lead study author Tuya Pal, MD, a clinical geneticist at the Moffitt Cancer Center in Tampa, Florida. Ultimately, it’s the patient who must decide whether to have genetic testing and take prophylactic measures for risk management, Pal said.

Accelerating oncology trials
DDN News – June 6
In an “unprecedented effort” to accelerate the discovery of life-saving cancer treatments, informatics solutions company M2Gen has launched a unique partnership of pharmaceuticals, academia and the Oncology Research Information Exchange Network (ORIEN)—an alliance of leading cancer centers throughout the United States founded in 2014—to share information and speed up targeted trials to ultimately combat and cure advanced-stage cancers. Celgene Corp. will be the industry’s founding member for a network of participants joining in this new initiative.

Potential Survival Advantage Observed for 177Lu-Dotatate in Midgut Neuroendocrine Tumors
Oncology Nurse Advisor – June 6
The agent results in clinically meaningful and statistically significant increases in progression-free survival and objective radiographic response rates, with a favorable safety profile, said Jonathan R. Strosberg, MD, Moffitt Cancer Center, Tampa, Florida.

Somatic genomic landscape of over 15,000 advanced-stage cancer patients
Medpage today – June 6, 2016
 

ASCO 2016: Minority BRCA-positive breast cancer survivors appear less likely to receive preventive surgery
eCancer News – June 6
“People only benefit from genetic testing for cancer risk if they act on the information the test reveals and receive appropriate follow-up care,” said lead study author Tuya Pal, MD, a Clinical Geneticist at the H. Lee Moffitt Cancer Center & Research Institute, Inc. in Tampa, Florida.

Moffitt collaboration accelerates blood cancer research
Tampa Bay Business Journal – June 6
Research teams at Moffitt Cancer Center will focus on blood cancers as part of a three-year collaboration with Incyte Corp.

Strategic approach helps providers benefit from portals
Health Data Management – June 6
"We asked our patients, who so generously donate us their time, tissue and blood samples, what we could give back to them, and they overwhelmingly said, 'Access to our data,'" says Jenn Camps, director of clinical systems at Moffitt Cancer Center in Tampa; she has a degree in marketing but works within Moffitt's IT department.

Black women are less likely to have breasts and ovaries removed to prevent cancer
STAT News – June 6
For the ASCO study, epidemiologist Dr. Tuya Pal and her colleagues at the Moffitt Cancer Center in Tampa surveyed breast cancer patients in Florida, all younger than 50 and diagnosed from 2009 to 2012.

Potential Survival Advantage Observed for 177Lu-Dotatate in Midgut Neuroendocrine Tumors
Oncology Nurse Advisor – June 6
The agent results in clinically meaningful and statistically significant increases in progression-free survival and objective radiographic response rates, with a favorable safety profile, said Jonathan R. Strosberg, MD, Moffitt Cancer Center, Tampa, Florida.

CPX-351 ‘new standard of care’ for older patients with secondary AML
Oncology Practice – June 6
In a video interview, primary investigator Dr. Jeffrey Lancet of H. Lee Moffitt Cancer Center & Research Institute, Tampa, Fla., discusses the data to be presented to the Food and Drug Administration for approval of the drug, and why the liposomal formulation of cytarabine and daunorubicin achieved superior results in these difficult to treat patients.

Final Phase III Data Uphold CPX-351 Survival Benefit in AML
OncLive – June 5
Jeffrey Lancet, MD, Moffitt Cancer Center

Doubling up on cancer immunotherapy shows promise, but side effects still a challenge
Cancer Research UK – June 4
Dr Scott Antonia, from the Moffitt Cancer Center in the US, is studying small cell lung cancer, which is difficult treat if it returns after chemotherapy. "It has been a stubborn disease, and not for the lack of trying," he told a packed room of scientists. 

Immunotherapy: A new cancer treatment using the body’s natural defenses
Christian Post – June 4
A new study by the Moffitt Cancer Center has revealed that the use of two immunotherapeutic agents, nivolumab and ipilimumab, is more effective in treating patients with small cell lung cancer who have failed to respond to initial chemotherapy.

CPX-351 Improved Survival in Older Patients With High-Risk Secondary AML
Cancer Network – June 4
“CPX-351 demonstrated superior efficacy compared to 7+3”—cytarabine 100 mg/m2/day for 7 days with daunorubicin 60 mg/m2 on days 1, 2, and 3—“in all key efficacy parameters,” said study presenter Jeffrey E. Lancet, MD, of H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida.

Somatic Genomic Landscape of over 15,000 Advanced-stage Cancer Patients
MedPage Today – June 4
Howard McLeod, PharmD, Moffitt Cancer Center

Nivolumab ± Ipilimumab Induces Durable Responses in Previously Treated SCLC
Cancer Therapy Advisor – June 4

"The majority of patients with SCLC respond to first-line chemotherapy, but everyone relapses," said lead investigator Scott J. Antonia, MD, department chair of the thoracic oncology department at the Moffitt Cancer Center in Tampa, FL. "Outcomes with second-line treatments are poor."

Metastatic breast cancer research initiative benefits from direct-to-patient recruitment
HemOnc Today – June 4

Perspective by Hatem Soliman, MD, Moffitt Cancer Center

Nivolumab/Ipilimumab Combination Active in Recurrent SCLC
OncLive – June 4
Scott Antonia, MD, Moffitt Cancer Center

If you get colon cancer, your prognosis depends partly on where it started
Washington Post – May 18
Richard Kim, an associate professor in the department of gastrointestinal oncology at Moffitt Cancer Center in Tampa, said he wasn’t surprised by the results because earlier studies had pointed to similar, if less definitive, conclusions.

###

Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.